22 related articles for article (PubMed ID: 3484679)
1. Impact of intravenous/intranasal polyinosinic-polycytidylic acid administration on the mediastinal fat-associated lymphoid clusters and lung tissue in healthy mice.
Elewa YHA; Khalifa AM; Zahran MH
Ann Anat; 2023 Oct; 250():152158. PubMed ID: 37666464
[TBL] [Abstract][Full Text] [Related]
2. Immune Priming of Pacific Oysters (
de Kantzow M; Hick PM; Whittington RJ
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766349
[TBL] [Abstract][Full Text] [Related]
3. Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses.
Hotz C; Treinies M; Mottas I; Rötzer LC; Oberson A; Spagnuolo L; Perdicchio M; Spinetti T; Herbst T; Bourquin C
Oncoimmunology; 2016; 5(11):e1232219. PubMed ID: 27999742
[TBL] [Abstract][Full Text] [Related]
4. Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy.
Schomburg A; Kirchner H; Atzpodien J
J Cancer Res Clin Oncol; 1993; 119(12):745-55. PubMed ID: 8408187
[TBL] [Abstract][Full Text] [Related]
5. Antitumor response to recombinant murine interferon gamma correlates with enhanced immune function of organ-associated, but not recirculating cytolytic T lymphocytes and macrophages.
Black PL; Phillips H; Tribble HR; Pennington R; Schneider M; Talmadge JE
Cancer Immunol Immunother; 1993 Oct; 37(5):299-306. PubMed ID: 8402733
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of interleukin-2 and mismatched double-stranded RNA, individually and in combination, against a human malignant melanoma xenograft.
Hubbell HR; Vargas HE; Tsujimoto KL; Gibson GD; Pequignot EC; Bigler RD; Carter WA; Strayer DR
Cancer Immunol Immunother; 1992; 35(3):151-7. PubMed ID: 1638550
[TBL] [Abstract][Full Text] [Related]
7. The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers.
Talmadge JE; Herberman RB
Cancer Treat Rep; 1986 Jan; 70(1):171-82. PubMed ID: 3510733
[No Abstract] [Full Text] [Related]
8. Toxicity of polyinosinic-polycytidylic acid admixed with poly-L-lysine and solubilized with carboxymethylcellulose in mice.
Hartmann D; Schneider MA; Lenz BF; Talmadge JE
Pathol Immunopathol Res; 1987; 6(1):37-50. PubMed ID: 3447151
[TBL] [Abstract][Full Text] [Related]
9. Effect of tumor burden and route of administration on the immunotherapeutic properties of polyinosinic-polycytidylic acid stabilized with poly-L-lysine in carboxymethyl cellulose [Poly(I,C)-LC].
Black PL; Hartmann D; Pennington R; Phillips H; Schneider M; Tribble HR; Talmadge JE
Int J Immunopharmacol; 1992 Nov; 14(8):1341-53. PubMed ID: 1464467
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapeutic potential in murine tumor models of polyinosinic-polycytidylic acid and poly-L-lysine solubilized by carboxymethylcellulose.
Talmadge JE; Adams J; Phillips H; Collins M; Lenz B; Schneider M; Chirigos M
Cancer Res; 1985 Mar; 45(3):1066-72. PubMed ID: 3971361
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose.
Talmadge JE; Adams J; Phillips H; Collins M; Lenz B; Schneider M; Schlick E; Ruffmann R; Wiltrout RH; Chirigos MA
Cancer Res; 1985 Mar; 45(3):1058-65. PubMed ID: 3155990
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and therapeutic activity of polyinosinic-polycytidylic acid stabilized with poly-L-lysine in carboxymethylcellulose [poly(I,C)-LC].
Chirigos MA; Schlick E; Ruffmann R; Budzynski W; Sinibaldi P; Gruys E
J Biol Response Mod; 1985 Dec; 4(6):621-7. PubMed ID: 4087033
[TBL] [Abstract][Full Text] [Related]
13. Dissociation of therapeutic and toxic effects of polyinosinic-polycytidylic acid admixed with poly-L-lysine and solubilized with carboxymethyl cellulose in tumor-bearing mice.
Hartmann D; Adams JS; Meeker AK; Schneider MA; Lenz BF; Talmadge JE
Cancer Res; 1986 Mar; 46(3):1331-8. PubMed ID: 3484679
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
